Sulfinpyrazone in the Prevention of Sudden Death after Myocardial Infarction

Abstract
We report the results of a randomized, double-blind, multicenter trial comparing sulfinpyrazone (200 mg four times a day) and a placebo in the prevention of cardiac mortality among 1558 patients followed for an average of 16 months, beginning 25 to 35 days after a documented myocardial infarction.